全文获取类型
| 收费全文 | 6476篇 |
| 免费 | 823篇 |
| 国内免费 | 74篇 |
专业分类
| 耳鼻咽喉 | 27篇 |
| 儿科学 | 169篇 |
| 妇产科学 | 92篇 |
| 基础医学 | 823篇 |
| 口腔科学 | 163篇 |
| 临床医学 | 698篇 |
| 内科学 | 1512篇 |
| 皮肤病学 | 70篇 |
| 神经病学 | 458篇 |
| 特种医学 | 586篇 |
| 外科学 | 939篇 |
| 综合类 | 140篇 |
| 一般理论 | 2篇 |
| 预防医学 | 688篇 |
| 眼科学 | 66篇 |
| 药学 | 540篇 |
| 中国医学 | 2篇 |
| 肿瘤学 | 398篇 |
出版年
| 2021年 | 80篇 |
| 2020年 | 46篇 |
| 2019年 | 76篇 |
| 2018年 | 99篇 |
| 2017年 | 85篇 |
| 2016年 | 104篇 |
| 2015年 | 100篇 |
| 2014年 | 141篇 |
| 2013年 | 193篇 |
| 2012年 | 256篇 |
| 2011年 | 298篇 |
| 2010年 | 193篇 |
| 2009年 | 181篇 |
| 2008年 | 232篇 |
| 2007年 | 298篇 |
| 2006年 | 289篇 |
| 2005年 | 256篇 |
| 2004年 | 258篇 |
| 2003年 | 230篇 |
| 2002年 | 246篇 |
| 2001年 | 200篇 |
| 2000年 | 223篇 |
| 1999年 | 181篇 |
| 1998年 | 136篇 |
| 1997年 | 118篇 |
| 1996年 | 121篇 |
| 1995年 | 124篇 |
| 1994年 | 93篇 |
| 1993年 | 102篇 |
| 1992年 | 126篇 |
| 1991年 | 127篇 |
| 1990年 | 122篇 |
| 1989年 | 159篇 |
| 1988年 | 130篇 |
| 1987年 | 154篇 |
| 1986年 | 130篇 |
| 1985年 | 125篇 |
| 1984年 | 120篇 |
| 1983年 | 105篇 |
| 1982年 | 75篇 |
| 1981年 | 84篇 |
| 1980年 | 65篇 |
| 1979年 | 77篇 |
| 1978年 | 49篇 |
| 1977年 | 62篇 |
| 1974年 | 53篇 |
| 1972年 | 62篇 |
| 1970年 | 53篇 |
| 1969年 | 45篇 |
| 1968年 | 44篇 |
排序方式： 共有7373条查询结果，搜索用时 15 毫秒
1.
Anthony J. Bleyer Vincent A. Scavo Samuel E. Wilson Barry J. Browne Brian L. Ferris C. Keith Ozaki Timmy Lee Eric K. Peden Bradley S. Dixon Rick Mishler Timothy P. O&#x;Connor Kendrah Kidd Steven K. Burke 《Journal of vascular surgery》2019,69(2):507-515
Objective
Arteriovenous fistulas created in patients with chronic kidney disease often lose patency and fail to become usable. This prospective trial evaluated the efficacy of vonapanitase, a recombinant human elastase, in promoting radiocephalic fistula patency and use for hemodialysis.Methods
PATENCY-1 was a double-blind, placebo-controlled trial that enrolled 349 patients on or approaching hemodialysis and being evaluated for radiocephalic arteriovenous fistula creation. Of these, 313 were randomized and 311 treated. Patients were assigned to vonapanitase (n = 210) or placebo (n = 103). The study drug solution was applied topically to the artery and vein for 10 minutes immediately after fistula creation. The primary and secondary end points were primary patency (time to first thrombosis or corrective procedure) and secondary patency (time to abandonment). Tertiary end points included use of the fistula for hemodialysis, fistula maturation by ultrasound, and procedure rates.Results
The Kaplan-Meier estimates of 12-month primary patency were 42% (95% confidence interval [CI], 35-49) and 31% (95% CI, 21-42) for vonapanitase and placebo (P = .25). The Kaplan-Meier estimates of 12-month secondary patency were 74% (95% CI, 68-80) and 61% (95% CI, 51-71) for vonapanitase and placebo (P = .048). The proportions of vonapanitase and placebo patients were 39% and 25% (P = .035) with unassisted use for hemodialysis and 64% and 44% (P = .006) with unassisted plus assisted use.Conclusions
Vonapanitase treatment did not significantly improve primary patency but was associated with increased secondary patency and use for hemodialysis. Further research is needed to evaluate these end points. 相似文献2.
3.
Social media has become a major platform for debates on science and health. This commentary argues that while social media can present challenges to communicating important health matters, it can also provide health experts a unique opportunity to engage with and build trust among members of the public. 相似文献
4.
5.
6.
Start Amanda R. Amiya Rachel M. Dixon Alexis C. Britt Thomas W. Toblin Robin L. Adler Amy B. 《Prevention science》2020,21(6):784-794
Prevention Science - The LINKS curriculum, adapted from Britt et al. (2018a), was designed to improve unit climate, knowledge, and attitudes about mental health treatment seeking in military... 相似文献
7.
Nicolas Farina Ben Hicks Kate Baxter Yvonne Birks Carol Brayne Margaret Dangoor Josie Dixon Peter R. Harris Bo Hu Martin Knapp Eleanor Miles Rotem Perach Sanna Read Louise Robinson Jennifer Rusted Rob Stewart Alan Thomas Raphael Wittenberg Sube Banerjee 《International journal of geriatric psychiatry》2020,35(3):290-301
8.
Aaron K. Apawu Stephanie M. Curley Angela R. Dixon Mirabela Hali Moaz Sinan Rod D. Braun James Castracane Anthony T. Cacace Magnus Bergkvist Avril Genene Holt 《Nanomedicine : nanotechnology, biology, and medicine》2018,14(7):1999-2008
Fundamental challenges of targeting specific brain regions for treatment using pharmacotherapeutic nanoparticle (NP) carriers include circumventing the blood–brain-barrier (BBB) and tracking delivery. Angiopep-2 (AP2) has been shown to facilitate the transport of large macromolecules and synthetic nanoparticles across the BBB. Thus, conjugation of AP2 to an MS2 bacteriophage based NP should also permit transport across the BBB. We have fabricated and tested a novel MS2 capsid-based NP conjugated to the ligand AP2. The reaction efficiency was determined to be over 70%, with up to two angiopep-2 conjugated per MS2 capsid protein. When linked with a porphyrin ring, manganese (Mn2+) remained stable within MS2 and was MRI detectable. Nanoparticles were introduced intracerebroventricularly or systemically. Systemic delivery yielded dose dependent, non-toxic accumulation of NPs in the midbrain. Design of a multifunctional MRI compatible NP platform provides a significant step forward for the diagnosis and treatment of intractable brain conditions, such as tinnitus. 相似文献
9.